In this study, we conducted a comprehensive analysis of plasma proteomic alterations associated with varying severities of irAEs across a pan-cancer cohort of patients receiving anti-PD-1/PD-L1 immunotherapy as (neo)adjuvant therapy in combination with chemotherapy. The gene discussed is CD274; the disease is cancer.